doxapram has been researched along with Lung Diseases in 5 studies
Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.
Lung Diseases: Pathological processes involving any part of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants." | 9.41 | Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023) |
| "To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants." | 5.41 | Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023) |
| "In a double-blind study patients given a single dose of doxapram 1-5-2-0 mg/kg combined with morphine postoperatively had a significantly lower incidence of reflex postoperative cough and expectoration of purulent sputum than patients given morphine alone." | 5.04 | Role of doxapram in reducing pulmonary complications after major surgery. ( Dundee, JW; Gawley, TH; Gupta, PK; Jones, CJ, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (80.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Evans, S | 1 |
| Avdic, E | 1 |
| Pessano, S | 1 |
| Fiander, M | 1 |
| Soll, R | 1 |
| Bruschettini, M | 1 |
| Drummond, GB | 1 |
| Park, GR | 1 |
| Steele, RJ | 1 |
| Walker, WS | 1 |
| Irvine, MK | 1 |
| Lee, D | 1 |
| Taylor, TV | 1 |
| Gawley, TH | 1 |
| Dundee, JW | 1 |
| Gupta, PK | 1 |
| Jones, CJ | 1 |
| Andersen, R | 1 |
| Krohg, K | 1 |
1 review available for doxapram and Lung Diseases
| Article | Year |
|---|---|
Doxapram for the prevention and treatment of apnea in preterm infants.
Topics: Aminophylline; Apnea; Caffeine; Doxapram; Humans; Infant, Newborn; Infant, Premature; Lung Diseases | 2023 |
3 trials available for doxapram and Lung Diseases
| Article | Year |
|---|---|
Doxapram and postoperative chest complications.
Topics: Abdomen; Clinical Trials as Topic; Cough; Double-Blind Method; Doxapram; Female; Humans; Lung Diseas | 1983 |
The use of doxapram in the prevention of postoperative pulmonary complications.
Topics: Clinical Trials as Topic; Doxapram; Female; Humans; Lung Diseases; Male; Postoperative Complications | 1982 |
Role of doxapram in reducing pulmonary complications after major surgery.
Topics: Adolescent; Adult; Clinical Trials as Topic; Cough; Doxapram; Female; Humans; Lung Diseases; Male; M | 1976 |
1 other study available for doxapram and Lung Diseases
| Article | Year |
|---|---|
Prevention of postoperative pulmonary complications. Intravenous analgesia combined with doxapram.
Topics: Doxapram; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Lung | 1976 |